Results 101 to 110 of about 6,006,073 (362)

Advances in covalent drug discovery

Nature reviews. Drug discovery, 2022
Covalent drugs have been used to treat diseases for more than a century, but tools that facilitate the rational design of covalent drugs have emerged more recently.
L. Boike, Nathaniel J. Henning, Daniel K. Nomura   +2 more
semanticscholar   +1 more source

Antibiotic drug discovery [PDF]

Microbial Biotechnology, 2016
Summary Due to the threat posed by the increase of highly resistant pathogenic bacteria, there is an urgent need for new antibiotics; all the more so since in the last 20 years, the approval for new antibacterial agents had decreased. The field of natural product discovery has undergone a tremendous development over the past few years.
Wohlleben, Wolfgang, Mast, Yvonne, Stegmann, Evi, Ziemert, Nadine   +3 more
openaire   +2 more sources

Measurable Residual Disease Monitoring During Treatment for Pediatric Acute Myeloid Leukemia in First Relapse

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Survival after relapse in pediatric acute myeloid leukemia (AML) remains poor, highlighting the critical importance of identifying prognostic factors to guide optimal relapse management. Methods We investigated the prognostic impact of multiparameter flow cytometry (MFC) measurable residual disease (MRD) in 188 patients with first ...
Camilla Poulsen, Kristian Juul Sandahl, Lene Karlsson, Jonas Abrahamsson, Nira Arad‐Cohen, Daniel Cheuk, Barbara De Moerloose, Linda Fogelstrand, Jose Maria Fernandez Navarro, Bianca F. Goemans, Kirsi Jahnukainen, Gertjan Kaspers, Zhanna Kovalova, Monica Cheng Munthe‐Kaas, Ulrika Norén‐Nyström, Josefine Palle, Ramune Pasauliene, Cornelis Jan Pronk, Kadri Saks, Anne Tierens, Henrik Hasle, Kristian Løvvik Juul‐Dam   +21 more
wiley   +1 more source

FAIR data management: what does it mean for drug discovery? [PDF]

The drug discovery community faces high costs in bringing safe and effective medicines to market, in part due to the rising volume and complexity of data which must be generated during the research and development process.
Gribbon, Philip, Satagopam, Venkata P., Gu, Wei, Henderson, David A., Sansone, Susanna Assunta, Gadiya, Yojana, Rocca-Serra, Philippe, Ioannidis, Vassilios   +7 more
core   +1 more source

Structure-based ligand design to overcome CYP inhibition in drug discovery projects [PDF]

, 2014
Cytochrome P450 (CYP) enzymes are key players in xenobiotic metabolism, and inhibition of CYPs can therefore result in unwanted drug-drug interactions. Within drug discovery, CYP inhibition can cause delays in the progression of candidate drugs, or even ...
Brändén, Gisela,, Xue, Y. F., Schnecke, V., Sjogren, T.   +3 more
core   +1 more source

Dydrogesterone and Letrozole Combination for the Treatment of Endometriosis: A Mechanism-Based Therapeutic Approach

Obstetrics and Gynecology International
Endometriosis is a complex, estrogen-dependent disease with limited effective treatments that often focus on symptom management rather than addressing the underlying pathology.
Santosh Kumar Rai, Rakesh Kumar, Mohd Imran Khan, Anil Kumar   +3 more
doaj   +1 more source

Antiplasmodial activity of the natural product compounds alstonine and himbeline

International Journal for Parasitology: Drugs and Drug Resistance, 2021
Malaria, caused by Plasmodium parasites, continues to be a devastating global health issue. Despite a decline in malaria related deaths over the last decade, overall progress has plateaued.
M.S.J. Arnold, J.R. Macdonald, R.J. Quinn, T.S. Skinner-Adams, K.T. Andrews, G.M. Fisher   +5 more
doaj   +1 more source

The Relationship Between Physical Activity and Left Ventricular Remodeling in Childhood Cancer Survivors Treated With Anthracyclines: A Cross‐Sectional Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Introduction Anthracycline‐related cardiac remodeling precedes heart failure in childhood cancer survivors. The objectives of this study were to determine the relationships between patient‐specific factors, moderate‐to‐vigorous physical activity (MVPA), and cardiac remodeling.
Hari K. Narayan, Sitong Chen, F. Lennie Wong, Nathan Young, Anna Qi, Christopher Davis, Sanjeet Hegde, Nicholas Gloude, Kasey J. Leger, Kelly D. Getz, Francisco Contijoch, Kirsten Ness, Bonnie Ky, Dennis Kuo, Sheri J. Hartman, Saro H. Armenian   +15 more
wiley   +1 more source

Dual-targeted bacterial outer membrane vesicles enhance glioblastoma immunotherapy by regulating tumor microenvironment and inducing IFN-γ-mediated ferroptosis

Journal of Nanobiotechnology
Glioblastoma (GBM) immunotherapy is limited by the blood-brain barrier (BBB) and the tumor immune resistance. Here, we develop an engineered bacterial outer membrane vesicle (OMV) through safe and straightforward genetic modification of Escherichia coli,
Chen Chen, Xiaojing Zhu, Zefeng Song, Yutong Xing, Wenrui Jin, Fan Li, Pir Tariq Shah, Siqi Song, Haoran Geng, Kai Xu, Hong Wang, Zhenyong Wu   +11 more
doaj   +1 more source

How drug repurposing can advance drug discovery: challenges and opportunities

Frontiers in Drug Discovery
Traditional de novo drug discovery, which typically presents an 11% approval rate from phase I trials and even higher failure rates in fields like neurodegeneration, often requires two to three billion dollars and 10–17 years per new drug.
Luca Pinzi, Nicolò Bisi, G. Rastelli
semanticscholar   +1 more source